S-1 plus oxaliplatin

Phase 3Small molecule

S-1 plus oxaliplatin is one of 131 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Intestinal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Intestinal CancerPhase 2

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 2

Endostar

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

1 3

S-1 plus oxaliplatin

FFudan University

Phase 3

2 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Glutamine

Sanofi

Preclinical

1 9

Induction Phase1

Genmab

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastric Cancer2 trials

A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer

Terminated·YYonsei University·Phase 2·NCT01946061·3 enrolled

Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01795027·724 enrolled

Nasopharyngeal Carcinoma1 trial

SOX as Salvage Treatment in Nasopharyngeal Carcinoma

Terminated·FFudan University·Phase 2·NCT01403259·16 enrolled

Gastric Adenocarcinoma1 trial

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Unknown status·AAiping Zhou·Phase 2·NCT05218148·44 enrolled

Intestinal Cancer1 trial

Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer

Unknown status·XXijing Hospital·Phase 2·NCT01608646·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for S-1 plus oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S-1 plus oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S-1 plus oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFudan University

S-1 plus oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastric Cancer2 trials

Nasopharyngeal Carcinoma1 trial

Gastric Adenocarcinoma1 trial

Intestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News